Supplementary MaterialsSupplementary Table 1: Genetic mutational profiles of MDS patients with or without AID kjim-2018-247-suppl1. in 16 of 73 patients (21.9%). Mutations were detected in 57 (78.1%) patients. The percentage (68.8% vs. 80.7%, = 0.32) and the mean number of mutations (1.8 1.6 vs. 2.2 1.8, = 0.34) in MDS patients with or without AID were similar. However, the ten-eleven translocation- 2 (= 0.001). All mutations were variants of strong clinical significance. Conclusions Mutation of in patients with MDS may be associated with increased risk of developing AID. test and 5(6)-Carboxyfluorescein the chi-square test were used to compare continuous or categorical variables between the two groups. A values 0.05 were considered statistically significant. All statistical analyses were performed using SPSS version 23.0 (IBM Co., Armonk, NY, USA). RESULTS Baseline characteristics of MDS patients with or without AID The median age of the 73 MDS patients was 70 years (IQR, 56 to 75), and 49 patients (67.1%) were male. The median follow-up duration after MDS diagnosis was 1.8 years (IQR, 0.9 to 3.3). Among the 73 patients, 16 (21.9%) were diagnosed with 5(6)-Carboxyfluorescein an AID: four (25%) with autoimmune thyroiditis, three (18.8%) with immune thrombocytopenia, two (12.5%) with HA, one (6.3%) with RA, one (6.3%) with panniculitis, and one (6.3%) with idiopathic inflammatory myopathy (Fig. 2). The baseline characteristics of MDS patients with or without an AID are shown in Table 1. The two groups did not differ in terms of sex, age, MDS subtype, and laboratory parameters. Open in a separate window Physique 2. Temporal association between autoimmune disease and myelodysplastic syndrome (MDS) diagnosis. Among the 73 patients, 16 (21.9%) were diagnosed with an AID: four (25%) autoimmune thyroiditis, three (18.8%) immune thrombocytopenia, two (12.5%) hemolytic anemia, one (6.3%) RA, one (6.3%) panniculitis, one (6.3%) idiopathic inflammatory myopathy. Table 1. Baseline characteristics in MDS patients with AID or without AID valuemutation is associated with increased risk of 5(6)-Carboxyfluorescein autoimmunity in MDS patients The 88 selected genes sequenced herein are listed in Supplementary Table 1. Fifty-seven of 73 MDS patients (78.1%) harbored a genetic mutation in at least one of the selected genes. The presence of a mutation (68.8% vs. 80.7%, = 0.32) and the mean number of mutations (1.8 1.6 vs. 2.2 1.8, = 0.34) did not differ between the AID and non-AID groups. Strikingly, the rate of mutation was significantly higher in MDS patients with an AID than AKT1 in those without (31.3% [n = 5/16] vs. 5.3% [n = 3/57], respectively; = 5(6)-Carboxyfluorescein 0.001). The patients with mutation were older than those without (75 [70.8C84] vs. 68 [55.5C73], = 0.02). However, the median age did not differ between the AID and non-AID patients (66.5 years [56.3C72.5] vs. 70 years [56C75], = 0.66) (Table 1). Logistic regression analysis revealed that mutation was associated significantly with an increased risk of AID (odds percentage [OR], 8.18; 95% confidence interval [CI], 1.70 to 39.38; = 0.009) (Table 2). All observed mutations were variants of strong medical significance, including stop-gain and frameshift deletion and insertion mutations (Table 3). Table 2. Regression analyses for the development of autoimmune diseases in MDS individuals valuemutation was enriched significantly in individuals with an Help weighed against those without. Subgroup evaluation of 43 MDS sufferers with out a karyotypic abnormality uncovered that three (30%) of ten sufferers with an Help harbored a mutation weighed against three of 33 sufferers (9%) lacking any Help (= 0.04) (data not shown). As a result, modifications on the gene level could be crucial for autoimmunity in MDS. is one of the TET family members and is important in changing 5-methyl-cytosine (5-mC) to 5-hydroxymethyl-cytosine (5-hmC) during DNA demethylation [19]. Appropriately,.